![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Background: The lysine salt of bendazac is a non-steroidal anti-inflammatory agent, and it is marketed exclusively for the treatment of cataracts. We report two cases of possible hepatotoxicity due to the use of bendazac lysine. Methods: Laboratory tests, serologic tests, abdominal sonography and scan were performed to study liver disease. Results: Reversible increases of the hepatic enzymes were found in both cases. Anemia was also found in one of the cases (case 1). Conclusions: Abnormal liver test results could be related to a possible liver injury attributed to the use of bendazac lysine.